89 annotations
Page 4 of 5
We continue to make progress against our plans to increase manufacturing capacity, the most ambitious expansion plan in our company's history.
(No comment added)
Transcript
2024 Q1
5 May 24
that
GLP-1 agonist - only 1 mechanism. Terzepitide is 2 mechanisms.
Transcript
2024 Q1
5 May 24
*orforglipron* - pill
Transcript
2024 Q1
5 May 24
our forgone is a complicated large small molecule, a large small molecule
(No comment added)
Transcript
2024 Q1
5 May 24
orforglipron, should we have positive Phase III readout that provides another relief valve in terms of just offering a different presentation
(No comment added)
Transcript
2024 Q1
5 May 24
I expect that the demand will be -- will outpace supply through this year, potentially next year
(No comment added)
Transcript
2024 Q1
5 May 24
We recently signed an agreement to acquire an injectable medicine facility from Nexus Pharmaceuticals in Pleasant Prairie, Wisconsin.
(No comment added)
Transcript
2024 Q1
5 May 24
it's not that we have a production issue
(No comment added)
Transcript
2024 Q1
5 May 24
we expect that the supply and demand situation will remain quite tight in the near term as well as the midterm
(No comment added)
Transcript
2024 Q1
5 May 24
We're doing construction overnight.
(No comment added)
Transcript
2024 Q1
2 May 24
we have sites working 24/7
(No comment added)
Transcript
2024 Q1
2 May 24
OSA impacts 80 million people in the U.S. with more than 20 million people suffering from moderate to severe OSA.
(No comment added)
Transcript
2024 Q1
2 May 24
The recent EMA approval and upcoming launch of our multi-dose quick pen delivery life for Mounjaro will unlock new supply capacity for Europe and other international markets
(No comment added)
Transcript
2024 Q1
2 May 24
do you expect Zepbound to get add to CMS in a similar way as [ WOGOBI ]
(No comment added)
Transcript
2024 Q1
2 May 24
, which evaluated tirzepatide for treatment of adults with obesities and moderate to severe obstructive sleep apnea known as OSA
(No comment added)
Transcript
2024 Q1
2 May 24
a positive Phase III results from the SURMOUNT-OSA studies
(No comment added)
Transcript
2024 Q1
2 May 24
we actually expect to get obstructive sleep apnea for Zepbound covered by CMS and Medicare at the time of launch
(No comment added)
Transcript
2024 Q1
2 May 24
positive Phase III results for tirzepatide in moderate to severe obstructive sleep apnea, the approval of our multi-dose quick pen delivery device for Mounjaro in Europe, submission of mirikizumab in the U.S. and EU for moderately to severely active Crohn's disease, the resubmission of lebrikizumab in the U.S. for moderate to severe atopic dermatitis and the initiation of our Phase III study for lepodisiran, evaluating efficacy and reducing cardiovascular risk
(No comment added)
Transcript
2024 Q1
2 May 24
that will be the opportunity to see the full NASH package from that Phase II trial
(No comment added)
Transcript
2024 Q1
2 May 24
the abstract was accepted and will be presented at EASL in early June
(No comment added)
Transcript
2024 Q1
2 May 24